Differentiation of Mammary Tumors by SKI-606 (bostutinib) (illumina)

ABSTRACT: While c-Src is infrequently mutated in human cancers, it mediates oncogenic signals of many activated growth factor receptors and thus remains a key potential target of cancer therapy. However, the widespread function of Src in many cell types and processes requires evaluation of Src-targeted therapeutics within a normal developmental and immune competent environment. In an effort to direct clinical use of Src inhibitors, we tested the effectiveness of one of the four Src inhibitors in clinical testing, SKI-606 (bosutinib), in the MMTV-PyVmT transgenic mouse model of breast cancer. Tumor formation in this model is dependent on the presence of Src, but the necessity of Src kinase activity for tumor formation has not been determined. Furthermore, Src inhibitors have not been examined in an a

ORGANISM(S): Mus musculus

SUBMITTER: Roy Williams 

PROVIDER: E-GEOD-20921 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress